Literature DB >> 9812171

Determination of p185 and adenylosuccinate lyase (ASL) activity in preneoplastic colon lesions and intestinal mucosa of human subjects.

L Terzuoli1, F Carlucci, A D Martino, B Frosi, B Porcelli, C Minacci, R Vernillo, L Baldi, E Marinello, R Pagani, A Tabucchi.   

Abstract

OBJECTIVES: The HER2 gene has been found amplified in a number of human adenocarcinoma leading to elevated levels of expression of its encoded product, p185 protein. Because little information is available on the tissue and tumor specificity of this gene product, we studied the expression of p185 protein in preneoplastic colon lesions. Adenylosuccinate lyase (ASL, EC 4.3.2.2) is known to increase in malignancies such as colorectal, breast, and prostate cancer. In order to evaluate the potential of ASL as a tumor marker, its activity was determined and compared with the expression of p185. DESIGN AND METHODS: p185 was determined by an immunohistochemical procedure in patients with the preneoplastic lesions. ASL activity was evaluated in intestinal mucosa adjacent to colorectal cancers (patient group A) and in preneoplastic colorectal lesions (group B). The enzyme activity was evaluated in dialyzed supernatants, following the disappearance of substrate (adenylosuccinate AMP-S) and the formation of product (adenosine 5'-monophosphate-AMP), separated by high performance liquid chromatography. RESULTS AND
CONCLUSIONS: Increased expression of p185 and elevated ASL activity were observed in tubular and tubulo-villous adenoma and may, therefore, be associated with the early stages of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9812171     DOI: 10.1016/s0009-9120(98)00058-7

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

1.  Adenylosuccinate lyase enhances aggressiveness of endometrial cancer by increasing killer cell lectin-like receptor C3 expression by fumarate.

Authors:  Haengki Park; Kenji Ohshima; Satoshi Nojima; Shinichiro Tahara; Masako Kurashige; Yumiko Hori; Daisuke Okuzaki; Naoki Wada; Jun-Ichiro Ikeda; Eiichi Morii
Journal:  Lab Invest       Date:  2018-02-21       Impact factor: 5.662

2.  Multiple biomarkers of colorectal tumor in a differential diagnosis model: a quantitative study.

Authors:  Wen Jin; Mei-Qin Gao; Zhi-Wu Lin; Dai-Xing Yang
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  Extramammary Paget's Disease of Anal Canal Associated With Rectal Adenoma Without Invasive Carcinoma.

Authors:  Vaibhav Chumbalkar; Timothy A Jennings; Sanaz Ainechi; Edward C Lee; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2016-12-23

4.  Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer.

Authors:  Giada Zurlo; Xijuan Liu; Mamoru Takada; Cheng Fan; Jeremy M Simon; Travis S Ptacek; Javier Rodriguez; Alex von Kriegsheim; Juan Liu; Jason W Locasale; Adam Robinson; Jing Zhang; Jessica M Holler; Baek Kim; Marie Zikánová; Jörgen Bierau; Ling Xie; Xian Chen; Mingjie Li; Charles M Perou; Qing Zhang
Journal:  Nat Commun       Date:  2019-11-15       Impact factor: 14.919

5.  Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis.

Authors:  Stephanie Taha-Mehlitz; Gaia Bianco; Mairene Coto-Llerena; Venkatesh Kancherla; Glenn R Bantug; John Gallon; Caner Ercan; Federica Panebianco; Serenella Eppenberger-Castori; Marco von Strauss; Sebastian Staubli; Martin Bolli; Ralph Peterli; Matthias S Matter; Luigi M Terracciano; Markus von Flüe; Charlotte K Y Ng; Savas D Soysal; Otto Kollmar; Salvatore Piscuoglio
Journal:  Theranostics       Date:  2021-02-15       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.